CN105326888A - Medicinal composition for treating child phlegm-heat obstructing lung type asthma - Google Patents
Medicinal composition for treating child phlegm-heat obstructing lung type asthma Download PDFInfo
- Publication number
- CN105326888A CN105326888A CN201510871918.8A CN201510871918A CN105326888A CN 105326888 A CN105326888 A CN 105326888A CN 201510871918 A CN201510871918 A CN 201510871918A CN 105326888 A CN105326888 A CN 105326888A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- phlegm
- children
- lung type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 62
- 210000004072 lung Anatomy 0.000 title claims abstract description 52
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 48
- 208000026435 phlegm Diseases 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 45
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 claims abstract description 27
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 26
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 claims abstract description 26
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 229940013618 stevioside Drugs 0.000 claims abstract description 25
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000019202 steviosides Nutrition 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims description 53
- 229940079593 drug Drugs 0.000 claims description 38
- 235000013399 edible fruits Nutrition 0.000 claims description 25
- 235000013580 sausages Nutrition 0.000 claims description 22
- 230000000274 adsorptive effect Effects 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 14
- 239000011347 resin Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 230000001476 alcoholic effect Effects 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 230000002879 macerating effect Effects 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000007796 conventional method Methods 0.000 claims description 4
- 241001219659 Climacium dendroides Species 0.000 abstract description 2
- 241000498899 Bidens frondosa Species 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000008773 effect on children Effects 0.000 abstract 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 17
- 206010047924 Wheezing Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 206010036790 Productive cough Diseases 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000003800 pharynx Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004681 ovum Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000008203 tachypnea Diseases 0.000 description 3
- 206010043089 tachypnoea Diseases 0.000 description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- IXHACUTUTOCSJE-UHFFFAOYSA-N Cyclolaudenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCC(C)C(C)=C)C)CCC3(C)C1CC2 IXHACUTUTOCSJE-UHFFFAOYSA-N 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 238000002555 auscultation Methods 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- IXHACUTUTOCSJE-HWTFXIFRSA-N cyclolaudenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CC[C@H](C)C(C)=C)C)CC[C@@]3(C)[C@@H]1CC2 IXHACUTUTOCSJE-HWTFXIFRSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- 235000020995 raw meat Nutrition 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- QCGMIFBWAQSUQY-UHFFFAOYSA-N 31-Norcyclolaudenol Natural products C1CC2(C)C(C(CCC(C)C(C)=C)C)CCC2(C)C2CCC3C(C)C(O)CCC33C21C3 QCGMIFBWAQSUQY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 241000644798 Canarium <sea snail> Species 0.000 description 1
- 244000298643 Cassia fistula Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000219428 Fagaceae Species 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000035756 Infantile asthma Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010059411 Prolonged expiration Diseases 0.000 description 1
- 241000921453 Rhodobryum Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- -1 and dry Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000010159 dioecy Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000014987 limb edema Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta (mosses)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition for treating child phlegm-heat obstructing lung type asthma and a preparation method thereof. The medicinal composition is prepared from climacium dendroides, bidens frondosa, stevioside, taraxerol and fructus cassiae fistulae. The medicinal composition can be prepared into various dosage forms according to a conventional preparation process, and is remarkable in treatment effect on child phlegm-heat obstructing lung type asthma.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to and a kind ofly treat pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma and preparation method thereof.
Background technology
Asthma is TCM Pediatrics commonly encountered diseases, every disease that is clinical manifestation with cough with asthma tachypnea, wheezing sound in the throat, even failing to lie flat due to dyspnea, opening mouth and lifting shoulder due to dyspnea, cyanotic lips can be included into traditional Chinese medical science asthma and carry out determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, comprises doctor trained in Western medicine asthmatic bronchitis, bronchiolitis, bronchial asthma etc.Children with asthma in recent years sickness rate, case fatality rate increases year by year, has become one of disease that vast department of pediatrics medical worker pays close attention to.Doctor trained in Western medicine uses hormone Inhalation in Treating to asthma in acute attack stage, dyspnea with rapid and short breath symptom controls ideal, but cough, abundant expectoration, pulmonary's rale sound are difficult to dissipation etc. and there is no good Therapeutic Method, and the glucocorticoid of prolonged application recommended dose also can produce systemic adverse reactions in various degree, symptoms of asthma still can not be made to control completely even if indivedual infant sucks the glucocorticoid exceeding recommended dose.The exploration effective Therapeutic Method of Chinese medicine and square medicine are the directions of middle medical circles effort at present.
Children's's the lung being usually insufficient, weakened defensive QI, hedge loosens, and cold warming up does not know self-regulated, is very easily subject to exopathogen invasion and attack, makes impaired depurative descending of lung QI, disturbance of lung-QI, abnormal rising of lung-QI, priming latent phlegm, and mental disorder is handed over and hindered in air flue, and ascending or descending movement of vital Qi is unfavorable, so that coughing and wheezing, wheezing sound in the throat, sends out as asthma.Children's spoils in Modern Family, usually feeds the food pursuing high protein, high nutrition, and children's all can hinder spleen to transport addicted to food salty sour savoury, fish raw meat stimulating food etc., makes raw expectorant heat, brings out phlegm-heat obstructing lung type asthma.Say as " Confucian's Duties to Their Parents ": " rich and honour person, the saliva of meaning is coughed, and polydipsia eats dense taste, and heat-phlegm becomes also." in addition primary disease be mainly in preschooler, the reflection of this age period children cough is poor, and expectoration is limited in one's ability, the sputum in air flue can not be excreted, and is also abundant expectoration when causing asthma attack, the treatment difficult point that disappears of wheezing sound in the throat phenomenon difficulty.
10000 years moss: this product is ten thousand Nian Xian sections, 10000 years Rhodobryum plants, 10000 years moss Climaciumdendroides(Hedw.) plant of Web.etMohr [ LeskeadendroidesHedw. ].Spring, summer gather, and clean, dry.[nature and flavor] are bitter; Cold.[function cures mainly] removing damp-heat; Relaxing muscles and tendons and activating QI and blood in the collateral.Main air wets impairment caused by overstrain; Bones and muscles pain.[chemical analysis] is containing cupreol (β-sitosterol), stigmasterol (stigmasterol), ergosterol (ergosterol), campesterol (campesterol), cyclolaudenol (cyclolaudenol), the nor-cyclolaudenol of 31-(31-norcyclolaudenol), and metallic elements of ferrum, manganese, zinc, copper etc.[former phytomorph] plant is thick in tree-like, and subterraneous stem crawls to grow wild, tool rhizoid and film quality squamous lobule.The aerial stem of plant is upright, multi-branched, and up to 15-20cm, branch gathers green palea.The leaf on stem top and the blade of branched base part are wide ovum shape triangle or ovum shape lanceolar, and base portion is slightly downward.Middle rib is single, reaches and stops before blade tip, the narrow rhombus of blade top cell, and leaf bight cell is circular, semi-transparent clear.The blade on branch top is less, and long and narrow lanceolar, leaf edge sawtooth reaches in middle part.Dioecism.Seta is elongated, long 2-4cm, red; Sporangium is upright, and long column shape, has more; The female shape of opercule height circle; Capsule balaclava shape, the full sporangium of clad.Record in Chinese medicine voluminous dictionary.
Large Herba Bidentis Tripartitae: this product is the dry aerial parts of the large Herba Bidentis Tripartitae BidensfrondosaL. of feverfew.6 ~ JIUYUE is gathered, and Herb or cutting, dry.[nature and flavor] are bitter, flat.[function with cure mainly] QI invigorating, heat clearing away.For body nihility power, night sweat, spitting of blood, dysentery.[character] this product Herb is logical straight, top tool branch.Stem is cylindrical, bottom tool wane and in class square, diameter 0.2 ~ 1.5cm, surperficial light brown to mulberry, tool longitudinal grin; Matter is crisp, frangibility, section canescence, the wide or hollow of marrow.Leaf is to life, and a winglike compound leaf, lobule 3 ~ 5 splits, and multireel is bent or broken. and in lanceolar after complete blade flattens, tip is gradually sharp, and there is rough sawn tooth at edge, and the back side is by sparse pubescence; The obvious petiolule of tool.Head inflorescence top is raw or axil is raw, and phyllary is most, outer lobate.Achene is flat, the shape of falling ovum wedge shape. and long 6 ~ llmm, top prickle 2 pieces, long 2 ~ 4mm, there is glochid both sides.Feeble QI, mildly bitter flavor.Record in Shanghai City Chinese crude drug standard 1994 (Shanghai Health Bureau).
Sausage fruit: this product is the dry mature fruit of leguminous plant Cassia fistula L. CassiafistulaL..Winter gathers when fruit is ripe, dries.[nature and flavor] are sweet, micro-pungent, cool.[function with cure mainly] removing heat from the liver, removing toxic substances, detumescence, captures.For hepatitis, liver poisoning, constipation, limb edema.[character] this product is cylindrical.Complete person long 30 ~ 50cm, diameter 1.5 ~ 2.5cm, top point, base portion has short fruit stem.Surface crineous, to pitchy, is smoothly with gloss, and the very obvious annular shallow slot of tool, it is obvious that abdomen carries on the back two sutures.Matter is hard, broken, section tool yellowish-brown tabula.1, each tool seed of every two compartment.Sarcocarp red and white around seed or yellow green are to yellowish-brown.Seed is attached on ventral suture by short-term shape funicle, often comes off.Seed is oval and slightly flat, and yellowish-brown is to reddish dark brown, smooth, and the wrinkle of both sides tool slightly protuberance, has shallow groove up and down.Matter is hard, and heat water produces the colloid membrane of transparent easy stripping, the flourishing cutin sample of endosperm.Sarcocarp gas is special, sweet in the mouth, hardship, puckery, sour.Record in health Tibetan medicine standard promulgated by the ministries or commissions of the Central Government (first), standard number: WS3-BC-0109-95.
Taraxerol (Taraxerol): CAS 127-22-0, molecular formula C
30h
50o, molecular weight 426.73.[pharmacological action] antiulcer, anti-gastric acid secretion.[ingredient origin] feverfew Europe Radix Taraxaci; Ebenaceae Diospyros plant, Fagaceae platymiscium, Canarium plant.
Stevioside (Stevioside): CAS 57817-89-7, molecular formula C
38h
60o
18, molecular weight 804.87.[pharmacological action] blood sugar lowering; Resisting hypertension; Enhance metabolism; Be used for the treatment of hyperchlorhydria.[ingredient origin] Folium Stevlae Rebaudianae Eupatoriumrebaudianum, Folium hydrangeae strigosae Rubussuavissimus.
2 crude drug chemical constitutions:
Taraxerol (Taraxerol) stevioside (Stevioside).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, pharmaceutical composition of a kind of effective treatment children's phlegm-heat obstructing lung type asthma and preparation method thereof is provided.
The present invention adopts following technical scheme to realize:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment children's phlegm-heat obstructing lung type asthma are:
10000 years moss 500-530 weight portion large Herba Bidentis Tripartitae 480-490 weight portion stevioside 22-28 weight portion taraxerol 18-19 weight portion sausage fruit 140-180 weight portions.
Preferably be used for the treatment of the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, be made up of the crude drug of following weight portion:
10000 years moss 515 weight portion large Herba Bidentis Tripartitae 485 weight portion stevioside 26 weight portion taraxerol 18.5 weight portion sausage fruit 160 weight portions.
Treat a pharmaceutical composition for children's's phlegm-heat obstructing lung type asthma, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a pharmaceutical composition for children's's phlegm-heat obstructing lung type asthma, it is characterized in that the treatment children's phlegm-heat obstructing lung type asthmatic medicament that pharmaceutical composition and chemical drugs or Chinese medicine form.
Treat a preparation method for the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: 10000 years moss 500-530 weight portion large Herba Bidentis Tripartitae 480-490 weight portion stevioside 22-28 weight portion taraxerol 18-19 weight portion sausage fruit 140-180 weight portions;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Preferably treat a preparation method for the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: 10000 years moss 515 weight portion large Herba Bidentis Tripartitae 485 weight portion stevioside 26 weight portion taraxerol 18.5 weight portion sausage fruit 160 weight portions;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Treat a preparation method for the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a preparation method for the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, it is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treat children's's phlegm-heat obstructing lung type asthmatic medicament.
Medicine composite for curing children's phlegm-heat obstructing lung type asthma is evident in efficacy: medicine composite for curing phlegm-heat obstructing lung type asthma, not only on comprehensive therapeutic effect, be obviously better than matched group, and at elimination sputum, alleviate breath with cough, wheezing sound in the throat single disease improvement aspect curative effect is also better than matched group.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are: 10000 years moss 515g large Herba Bidentis Tripartitae 485g stevioside 26g taraxerol 18.5g sausage fruit 160g;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Embodiment 2: pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are: 10000 years moss 500g large Herba Bidentis Tripartitae 490g stevioside 22g taraxerol 19g sausage fruit 140g;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Embodiment 3: pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are: 10000 years moss 530g large Herba Bidentis Tripartitae 480g stevioside 28g taraxerol 18g sausage fruit 180g;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 163g, adds starch 47g, mixing, granulates, dry, adds microcrystalline Cellulose 20g, magnesium stearate 2g, and mixing, is pressed into 1000, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 145g, adds starch 65g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains medicament composition capsule by encapsulated 1000.
Embodiment 6: the preparation of drop pill
Taking polyethylene glycol 6000 185g water-bath (80 DEG C) heating boils molten, add embodiment 3 pharmaceutical composition 25g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 4 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2.2cm apart from liquid level, drips speed with per minute 58 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Embodiment 7: the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are:
Large Herba Bidentis Tripartitae 410 weight portion taraxerol 16 weight portion sausage fruit 90 weight portions.
Embodiment 8: the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are:
Stevioside 2 weight portion taraxerol 4 weight portion sausage fruit 160 weight portions.
Embodiment 9: the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are:
Stevioside 5 weight portion taraxerol 3 weight portion sausage fruit 100 weight portions.
Experimental example 1: the experimental study for the treatment of children's phlegm-heat obstructing lung type asthma
1 clinical data
1.1 physical data
70 routine infants all from this provincial hospital Pediatric Clinic in year April in April, 2011 to 2012, all meet doctor trained in Western medicine Diagnosing Asthma standard and traditional Chinese medical science phlegm-heat obstructing lung type Diagnosing Asthma standard.Treatment group and each 35 examples of matched group are divided at random by 1: 1.Man 18 example in matched group, female 17 example; Year mean age (3.85 ± 2.45); Average course of disease (4.12 ± 1.69) d.Man 17 example in treatment group, female 18 example; Year mean age (4.21 ± 2.79); Average course of disease (3.95 ± 1.81) d.2 groups of infants are through statistical analysis in sex, age, the course of disease etc., and difference no statistical significance (P > 0.05), has comparability.
1.2 diagnostic criteria
1.2.1 Western medicine diagnose standard
With reference to the diagnostic criteria of " pediatrics " infantile asthma.1. the panting of recurrent exerbation, tachypnea, uncomfortable in chest or cough, many with contact allergen, cold air, physics or chemical irritation, viral upper and lower respiratory tract infection, to move etc. relevant.2. two lung audible and being dispersed in or the wheezing sound of diffusivity based on expiratory phase, expiratory phase prolongation during outbreak.3. bronchodilators has significant curative effect.Panting 4. caused by other diseases, tachypnea, uncomfortable in chest or cough.5. for the infant of atypical symptom, hear and wheezing sound person in pulmonary simultaneously, following any 1 Bronchodilation Test can be adopted as one sees fit to assist diagnosis, if positive diagnosable be asthma: quick-acting beta 2 receptor agonist atomized soln or aerosol suction, with 0.1% epinephrine 0.01mL/kg subcutaneous injection (maximum be no more than 0.3mL/ time).In 15 ~ 30min after carrying out above any a kind of test, obviously alleviate if panted, wheezing sound obviously minimizing person is positive.
1.2.2 traditional Chinese medical science Diagnosing Asthma standard
Formulate with reference to State Administration of Traditional Chinese Medicine's " Chinese medical disease Standardization of diagnosis and curative effect ".1. often have the premonitory symptom such as sneeze, cough before outbreak, or break out night.Wheezing between larynx during outbreak, dyspnea, expectoration is not well, very then can not put down sleeping, dysphoria etc.2. normal because of climate flip, suffer from cold or contact the factors such as some allergin and bring out.3. infancy stage eczema history or family's allergies can be had.4. heart and lung auscultation: two fullness of the lung cloth wheezing sounds, prolonged expiration, or hear and moist rales, increased heart rate.5. bronchial asthma, total white blood cells is normal, and eosinophilic granulocyte can increase, and suspicious allergen skin test is often positive.During companion's pulmonary infection, blood leukocytes sum and neutrophilic granulocyte can increase.
1.2.3 TCM syndrome diagnostic criteria
With reference to State Administration of Traditional Chinese Medicine's " Chinese medical disease Standardization of diagnosis and curative effect " syndrome of phlegm-heat obstructing lung: cough with asthma wheezing, yellowish thick sputum, xerostomia pharynx is red, or it is flushing to generate heat, and red tongue, yellow and thin fur or yellow greasy, slippery and rapid pulse, fingerprint is purple.
2 methods
2.1 matched group
Instruct according to asthma in acute attack stage treatment in pediatrics branch of Chinese Medical Association pneumatology group " During Prevention of Asthma in Children routine (trying) ", beclometasone μ g every day 200 ~ 400, albuterol sheet 0.1 ~ 0.15mg/kg, every day 2 ~ 3 times.
2.2 treatment group
Give pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20110130) 1-2 agent every day, every agent 3g, every agent 100mL that adds water dissolves, and points 3 times oral, and 7d is l the course for the treatment of, serve on 1 course for the treatment of.
2 groups of period in a medicine all avoid pungent food, raw meat is cold, greasy product.
2.3 statistical method
Use SPSS16.0 software to carry out statistical analysis, ranked data adopt Ridit inspection, and enumeration data adopts χ
2inspection, with P < 0.05 for difference has statistical significance.
3 results
3.1 criterion of therapeutical effect
With reference to the standard formulation in State Administration of Traditional Chinese Medicine's " new Chinese medicine guideline of clinical investigations ".Recovery from illness: transference cure, auscultation of lung is without wheezing sound.Effective: symptom is clearly better, pulmonary's wheezing sound obviously reduces.Effective: symptom takes a turn for the better to some extent, pulmonary's wheezing sound reduces.Invalid: symptom and wheezing sound are all without improvement.
3.2 disease criterions of therapeutical effect
Clinical recovery: tcm clinical practice symptom, sign disappear or substantially disappear, disease integration reduces >=95%.Effective: tcm clinical practice symptom, sign are obviously improved, disease integration reduces >=70%.Effective: tcm clinical practice symptom, sign all take a favorable turn, disease integration reduces >=30%.Invalid: to increase the weight of even tcm clinical practice symptom, sign are all not improved, disease integration reduces < 30%.
After 3.32 groups of infant treatments, comprehensive therapeutic effect compares
Treatment group recovery from illness 13 example, effective 13 examples, effective 4 examples, invalid 5 examples, total effective rate is 85.7%; Matched group recovery from illness 6 example, effective 8 examples, effective 12 examples, no effect 9, total effective rate is 74.3%.After 2 groups of treatments, comprehensive therapeutic effect comparing difference has statistical significance (P < 0.05).Refer to table 1.
After table 1 liang group infant treatment, comprehensive therapeutic effect compares (example)
Group | n | Recovery from illness | Effective | Effectively | Invalid | Total effective rate/% |
Matched group | 35 | 6 | 8 | 12 | 9 | 74.3 |
Treatment group | 35 | 13 | 13 | 4 | 5 | 85.7 * |
Note: compare with matched group
*p < 0.05.
TCM syndrome comparitive study after 3.42 groups of infant treatments
Treatment group clinical recovery 18 example, effective 8 examples, effective 5 examples, invalid 4 examples, total effective rate is 88.6%; Matched group recovery from illness 8 example, effective 3 examples, effective 15 examples, no effect 9, total effective rate is 74.3%.After 2 groups of treatments, TCM syndrome comparitive study difference has statistical significance (P < 0.05).Refer to table 2.
TCM syndrome comparitive study (example) after table 2 liang group infant treatment
Group | n | Recovery from illness | Effective | Effectively | Invalid | Total effective rate/% |
Matched group | 35 | 8 | 3 | 15 | 9 | 74.3 |
Treatment group | 35 | 18 | 8 | 5 | 4 | 88.6 * |
Note: compare with matched group
*p < 0.05.
Result shows, medicine composite for curing phlegm-heat obstructing lung type asthma, is not only obviously better than matched group on comprehensive therapeutic effect, and at elimination sputum, alleviate breath with cough, wheezing sound in the throat single disease improvement aspect curative effect is also better than matched group, can in clinical middle Coryza Treated by Syndrome Differentiation phlegm-heat obstructing lung type asthma.
Claims (8)
1. treat a pharmaceutical composition for children's's phlegm-heat obstructing lung type asthma, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
10000 years moss 500-530 weight portion large Herba Bidentis Tripartitae 480-490 weight portion stevioside 22-28 weight portion taraxerol 18-19 weight portion sausage fruit 140-180 weight portions.
2. a kind of pharmaceutical composition for the treatment of children's's phlegm-heat obstructing lung type asthma according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
10000 years moss 515 weight portion large Herba Bidentis Tripartitae 485 weight portion stevioside 26 weight portion taraxerol 18.5 weight portion sausage fruit 160 weight portions.
3. a kind of pharmaceutical composition for the treatment of children's's phlegm-heat obstructing lung type asthma according to claim 1, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition for the treatment of children's's phlegm-heat obstructing lung type asthma according to claim 1, is characterized in that the treatment children's phlegm-heat obstructing lung type asthmatic medicament that pharmaceutical composition and chemical drugs or Chinese medicine form.
5. treat a preparation method for the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: 10000 years moss 500-530 weight portion large Herba Bidentis Tripartitae 480-490 weight portion stevioside 22-28 weight portion taraxerol 18-19 weight portion sausage fruit 140-180 weight portions;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
6. a kind of preparation method for the treatment of the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma according to claim 5, is characterized in that preparing as follows:
The composition of crude drug and weight portion are: 10000 years moss 515 weight portion large Herba Bidentis Tripartitae 485 weight portion stevioside 26 weight portion taraxerol 18.5 weight portion sausage fruit 160 weight portions;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
7. a kind of preparation method for the treatment of the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma according to claim 5, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
8. a kind of preparation method for the treatment of the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma according to claim 5, is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treats children's's phlegm-heat obstructing lung type asthmatic medicament.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510871918.8A CN105326888A (en) | 2015-12-03 | 2015-12-03 | Medicinal composition for treating child phlegm-heat obstructing lung type asthma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510871918.8A CN105326888A (en) | 2015-12-03 | 2015-12-03 | Medicinal composition for treating child phlegm-heat obstructing lung type asthma |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105326888A true CN105326888A (en) | 2016-02-17 |
Family
ID=55277794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510871918.8A Withdrawn CN105326888A (en) | 2015-12-03 | 2015-12-03 | Medicinal composition for treating child phlegm-heat obstructing lung type asthma |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105326888A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106581100A (en) * | 2016-12-10 | 2017-04-26 | 济南昊雨青田医药技术有限公司 | Pharmaceutical composition for laryngitis treatment and preparation method thereof |
CN106692261A (en) * | 2016-12-10 | 2017-05-24 | 济南昊雨青田医药技术有限公司 | Pharmaceutical composition for treating laryngitis and preparation method thereof |
CN106727859A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | It is a kind of to treat pharmaceutical composition of pharyngitis and preparation method thereof |
CN106727774A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | Treat pharmaceutical composition of pharyngitis and preparation method thereof |
CN106852946A (en) * | 2016-12-10 | 2017-06-16 | 济南昊雨青田医药技术有限公司 | A kind of pharmaceutical composition for treating laryngitis |
-
2015
- 2015-12-03 CN CN201510871918.8A patent/CN105326888A/en not_active Withdrawn
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106581100A (en) * | 2016-12-10 | 2017-04-26 | 济南昊雨青田医药技术有限公司 | Pharmaceutical composition for laryngitis treatment and preparation method thereof |
CN106692261A (en) * | 2016-12-10 | 2017-05-24 | 济南昊雨青田医药技术有限公司 | Pharmaceutical composition for treating laryngitis and preparation method thereof |
CN106727859A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | It is a kind of to treat pharmaceutical composition of pharyngitis and preparation method thereof |
CN106727774A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | Treat pharmaceutical composition of pharyngitis and preparation method thereof |
CN106852946A (en) * | 2016-12-10 | 2017-06-16 | 济南昊雨青田医药技术有限公司 | A kind of pharmaceutical composition for treating laryngitis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104998098B (en) | It is a kind of to improve the solid beverage slept and preparation method | |
CN105326888A (en) | Medicinal composition for treating child phlegm-heat obstructing lung type asthma | |
CN1785024A (en) | Bag-tea for treating pharyngitis and beneficial for throat | |
CN103719491B (en) | A kind of sealwort invigorating the spleen moistening lung health protection tea and preparation method thereof | |
CN104547515A (en) | Tangerine pear syrup and preparation method thereof | |
CN102805776A (en) | Traditional Chinese medicine composition and preparation method of traditional Chinese medicine composition | |
CN110237174A (en) | A kind of eliminating dampness Chinese medicine composition and preparation method thereof for treating cold cough | |
CN106511740B (en) | A kind of product and preparation method thereof comprising ginseng | |
CN107625828A (en) | A kind of health protection tea for auxiliary treatment chronic pharyngitis, preparation method and application | |
CN105250843A (en) | Medicament for treating cough due to wind-heat evil | |
CN104840737B (en) | Chinese medicine composition with qi invigorating and lung moistening effect and its preparation method and application | |
CN104383232B (en) | Clearing heat and detoxicating buccal lozenge of lectuce tea and its production method | |
CN103989762B (en) | Chinese medicine composition of internal organs relieving cough and resolving phlegm and preparation method thereof is rushed down in a kind of heat clearing away | |
CN104510937A (en) | Traditional Chinese medicinal formula for treating infantile asthma and preparation method for paste of traditional Chinese medicinal formula | |
CN110025011A (en) | A kind of Radix Ophiopogonis ginseng lozenge of strengthen immunity | |
CN109663012A (en) | Dispelling wind and heat, removing toxic substances relieving sore-throat Chinese medicine composition and the preparation method and application thereof | |
CN108785559A (en) | A kind of drug and preparation method thereof for treating respiratory tract infection | |
CN104435860B (en) | Traditional Chinese medicinal preparation for treating infantile upper respiratory infection and preparation method of traditional Chinese medicinal preparation | |
CN106421591A (en) | Medicinal composition for treating narcolepsy and preparation method of medicinal composition | |
CN104127504B (en) | Infantile common cold cough syrup and preparation method thereof | |
CN105168860A (en) | Traditional Chinese medicine composite for treating infantile asthma and preparation method thereof | |
CN105288202A (en) | Pharmaceutical composition for curing infantile cough | |
CN104258361A (en) | Traditional Chinese medicine composition for treating infantile asthma | |
CN105055703A (en) | Anti-allergic traditional Chinese medicine composition and preparation method thereof | |
CN105079527B (en) | A kind of medicine for treating chronic urticaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160217 |
|
WW01 | Invention patent application withdrawn after publication |